Four children facing a “uniformly fatal” brain cancer are now alive years later after a new cell therapy shrank or erased their tumors, forcing the medical establishment to admit something extraordinary is happening.
Story Snapshot
- A new CAR T-cell therapy helped one child’s brain tumor disappear completely and stay gone more than four years.
- Trial children lived nearly twice as long as usual for this deadly cancer, with three surviving 3.5–4.5 years.
- Nine of eleven patients saw brain function improve, with some kids going from wheelchairs back to walking.
- The Food and Drug Administration granted a special fast-track status, signaling major potential but not full approval yet.
A Deadly Childhood Cancer Meets a Powerful New Weapon
Doctors call diffuse intrinsic pontine glioma, also known as diffuse midline glioma, one of the most hopeless childhood cancers. This tumor grows deep in the brainstem, where surgery is impossible and standard treatments barely slow it down. For decades, most children have survived only about eleven months after diagnosis, and many lose basic abilities like walking and talking as the disease spreads. Families have heard the same message again and again: nothing works, and there is no cure.
Stanford University researchers and their partners have tested a new approach that uses the child’s own immune system to attack the tumor. The treatment is called chimeric antigen receptor T-cell therapy, or CAR T-cell therapy, and it turns a patient’s T cells into guided “smart bombs” aimed at cancer. In this trial, doctors collected each child’s immune cells, engineered them to recognize a marker called GD2 on tumor cells, and then infused the cells back into the bloodstream and directly into the brain fluid. The goal was simple but bold: see if these engineered cells could reach the tumor and start killing cancer.
Remarkable Results: Tumors Shrink, One Disappears
The early results stunned even seasoned cancer experts. Out of eleven children and young adults treated in the Stanford-led study, nine showed clear neurological improvement as their tumors responded. Several patients regained lost abilities, including walking, hearing, and taste, after the cancer shrank. Imaging scans showed tumors in multiple patients shrank by more than half, with reported reductions of about 52 percent, 54 percent, and an astonishing 91 percent in different children. For families used to hearing only bad news, these changes were concrete and life-changing.
One child achieved what doctors call a complete response, meaning the tumor became undetectable on brain scans and has stayed that way. That boy remains cancer free more than four years after diagnosis, making this the first documented complete response for this type of brain cancer. Three trial patients overall have survived 3.5 to 4.5 years after starting treatment, far beyond the usual timeline where nearly every child dies within a year. As one outside expert noted, having several children alive around four years after diagnosis in this disease is “without precedent” and justifies real excitement.
Longer Survival, But Not Yet a General Cure
When researchers looked at survival across the group, they found the typical outcome changed in a big way. Trial participants lived a median of about 19.8 months after diagnosis, nearly double the historical eleven months for diffuse intrinsic pontine glioma. This means the “middle” patient in the study lived almost two years instead of less than one. That is a major step forward in a cancer long labeled “uniformly fatal,” and it offers families precious extra time with their children. Yet most kids still had some cancer left, so doctors describe this as strong disease control, not full cure.
Scientists involved in the trials stress that these are phase 1 studies built first to test safety. The sample size is tiny, and there is no randomized control group that received only standard care. Only one child so far has seen complete tumor disappearance, while most have partial responses or stable disease. Two children in one report progressed too quickly to even receive the therapy. Researchers openly say “much work remains” to refine and expand CAR T-cell treatment for this brain cancer and warn that survival gains, while real, do not yet prove a broad cure.
Managing Risks and Building a Path to Wider Use
The new therapy does come with risks that doctors are watching closely. Because CAR T cells ramp up the immune system inside the brain, some patients developed neuroinflammation that needed active medical care. In this trial, teams were able to manage these side effects, but they remain a serious concern as researchers try higher doses, different delivery routes, and combinations with other treatments. Experience from blood cancer CAR T therapies is helping teams better predict and handle problems like swelling and confusion. These safety lessons will shape how far and how fast this treatment can spread.
Everyone's racing to engineer T cells for solid tumors. One of the most striking pediatric brain-cancer results this year came from T cells that weren't engineered at all.
Children's National just published a Phase 1 in Nature Medicine: multi-antigen T cells targeting WT1, PRAME…
— BioSignal (@BioSignal) July 7, 2026
The United States Food and Drug Administration gave the Stanford therapy a special status called Regenerative Medicine Advanced Therapy, which is meant for treatments with strong potential to improve serious diseases. This designation speeds advice from regulators and can shorten the path to approval, but it does not itself make the therapy a standard covered treatment. Costs are another barrier, as CAR T therapies in other cancers can run around hundreds of thousands of dollars for a single course. That price tag raises hard questions about access for ordinary families if and when this therapy moves beyond trials.
Sources:
newscientist.com, pcrf-kids.org, ludwigcancerresearch.org, cancertodaymag.org, cancer.gov, facebook.com, seattlechildrens.org
